|
Atopic Dermatitis Drug |
For many adults and children with atopic dermatitis flare-ups, the standard dermatologic treatments are ineffective or too costly. Fortunately, several new drugs have been developed over the past decade or so that may provide a new and different way to manage this distressing skin condition. Topical corticosteroid and calcineurin inhibitors still remain most often mainstay treatment mainstees, with moisturizers sometimes being added. Corticosteroid products tend to be most effective for patients with mild to moderate cases of atopic dermatitis. Corticosteroid products also tend to be more effective if the disease is in remission.
Recently, two new drugs have been approved by the U.S. Food and Drug Administration (FDA). Accutane (finasteride) is a medication used to treat serious acne. It blocks the production of the major hormones that cause the sebaceous glands to produce excessive amounts of sebum, the skin's natural moisturizing substance. This can result in excessive facial oiliness, a condition known as acne vulgaris. Accutane is only recommended for patients diagnosed with non-cancerous skin conditions, such as those with non-melanoma skin cancer. The second new
atopic dermatitis drug, Orlistat, is also a prescription medication for almost clear skin. Like Accutane, Orlistat is only recommended for patients diagnosed with non-cancerous skin conditions. Orlistat is not effective for patients with atopic dermatitis. Although it was originally intended to treat obesity, it has been approved for almost clear skin conditions since 2021.
Several new atopic dermatitis drug ingredients are being tested for their effectiveness in the treatment of atopic dermatitis. Bacterial Vaginosis (BV) is a common vaginal infection that can cause severe itching and redness in the face and body. Atopic dermatitis drugs such as econazole, ketoconazole, and netilmycin are being investigated for their effectiveness in the treatment of eczema. One of the newest atopic dermatitis drugs, called jak inhibitors, is based on immunomodulators (antihistamines). Recently, in May 2020, Sanofi received the U.S. Food and Drug Administration (FDA) approval for Dupixent the first biologic medicine for children aged 6 to 11 years with moderate to severe atopic dermatitis.
Comments
Post a Comment